STOCK TITAN

[Form 4] Clover Health Investments, Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Karen M. Soares, General Counsel & Secretary of Clover Health Investments, Corp. (CLOV), reported a routine withholding of vested restricted stock units on August 14, 2025. The Form 4 shows 7,459 shares of Class A common stock were disposed of at an implicit withholding price of $2.57 per share to cover tax obligations tied to the vesting of 6.25% of RSUs originally granted on February 14, 2022. After this withholding, the Reporting Person beneficially owns 1,469,487 shares of Class A common stock.

The filing explains the RSU schedule: the 6.25% portion vested on August 14, 2025, with the remaining time‑based RSUs vesting in equal quarterly installments of 6.25% and a final vesting date of February 14, 2026, contingent on continued service. The Form 4 was signed by an attorney‑in‑fact on behalf of Ms. Soares on August 18, 2025.

Karen M. Soares, General Counsel & Secretary di Clover Health Investments, Corp. (CLOV), ha comunicato una ritenuta ordinaria su unità azionarie vincolate (RSU) maturate in data 14 agosto 2025. Il Modulo 4 indica che 7.459 azioni di azioni ordinarie di Classe A sono state cedute a un prezzo implicito di ritenuta di $2,57 per azione per coprire le imposte legate alla maturazione del 6,25% delle RSU originariamente assegnate il 14 febbraio 2022. Dopo questa ritenuta, la persona che presenta la comunicazione detiene beneficiariamente 1.469.487 azioni ordinarie di Classe A.

La comunicazione descrive il calendario delle RSU: la quota del 6,25% è maturata il 14 agosto 2025, mentre le restanti RSU basate sul tempo matureranno in quote trimestrali uguali del 6,25% con data finale di maturazione il 14 febbraio 2026, subordinata alla continuazione del servizio. Il Modulo 4 è stato firmato da un procuratore il 18 agosto 2025 per conto della Sig.ra Soares.

Karen M. Soares, Consejera General y Secretaria de Clover Health Investments, Corp. (CLOV), reportó una retención rutinaria de unidades de acciones restringidas (RSU) adquiridas el 14 de agosto de 2025. El Formulario 4 muestra que se dispusieron 7.459 acciones ordinarias de Clase A a un precio implícito de retención de $2,57 por acción para cubrir obligaciones fiscales vinculadas al otorgamiento del 6,25% de las RSU originalmente concedidas el 14 de febrero de 2022. Tras esta retención, la persona informante posee beneficiariamente 1.469.487 acciones ordinarias de Clase A.

La presentación explica el calendario de las RSU: la porción del 6,25% venció el 14 de agosto de 2025, y las RSU restantes basadas en el tiempo vencerán en cuotas trimestrales iguales del 6,25% con una fecha final de vencimiento el 14 de febrero de 2026, condicionada a la continuidad del servicio. El Formulario 4 fue firmado por un apoderado en nombre de la Sra. Soares el 18 de agosto de 2025.

클로버 헬스 인베스트먼트 코퍼레이션(CLOV)의 법률 고문 겸 서기인 카렌 M. 소아레스(Karen M. Soares)는 2025년 8월 14일에 취득한 제한부주식단위(RSU)에 대해 통상적인 원천징수를 보고했습니다. Form 4에 따르면 7,459주 클래스 A 보통주가 주당 $2.57의 암묵적 원천징수 가격으로 처분되어 2022년 2월 14일에 원래 부여된 RSU의 6.25%의 취득과 관련된 세금 의무를 충당했습니다. 이 원천징수 후 보고인은 클래스 A 보통주 1,469,487주를 실질적으로 보유하게 되었습니다.

보고서에는 RSU 일정이 설명되어 있습니다: 6.25% 분량은 2025년 8월 14일에 취득되었고, 나머지 기간기반 RSU는 동일한 분기별 6.25%씩 분할 취득되며 최종 취득일은 2026년 2월 14일로서 계속 근무가 조건입니다. Form 4는 2025년 8월 18일 소아레스 씨를 대신하여 법정대리인(변호사)이 서명했습니다.

Karen M. Soares, conseillère juridique générale et secrétaire de Clover Health Investments, Corp. (CLOV), a signalé une retenue courante sur des unités d'actions restreintes (RSU) acquises le 14 août 2025. Le formulaire 4 indique que 7 459 actions ordinaires de classe A ont été cédées à un prix implicite de retenue de 2,57 $ par action pour couvrir des obligations fiscales liées à la vesting de 6,25 % des RSU initialement attribuées le 14 février 2022. Après cette retenue, la personne déclarante détient bénéficiairement 1 469 487 actions ordinaires de classe A.

Le dépôt explique le calendrier des RSU : la tranche de 6,25 % a vesté le 14 août 2025, les RSU restantes liées au temps vestant par tranches trimestrielles égales de 6,25 % avec une date finale de vesting le 14 février 2026, sous réserve de la poursuite du service. Le formulaire 4 a été signé le 18 août 2025 par un mandataire au nom de Mme Soares.

Karen M. Soares, General Counsel & Secretary von Clover Health Investments, Corp. (CLOV), meldete eine routinemäßige Einbehaltung von ausgeübten Restricted Stock Units (RSUs) am 14. August 2025. Das Formular 4 zeigt, dass 7.459 Aktien der Klasse A zum impliziten Einbehaltungspreis von $2,57 je Aktie veräußert wurden, um steuerliche Verpflichtungen im Zusammenhang mit der Vesting von 6,25% der ursprünglich am 14. Februar 2022 gewährten RSUs zu decken. Nach dieser Einbehaltung besitzt die meldepflichtige Person wirtschaftlich 1.469.487 Aktien der Klasse A.

Die Einreichung erläutert den RSU-Zeitplan: Der 6,25%-Anteil ist am 14. August 2025 vested, die verbleibenden zeitabhängigen RSUs vesten in gleichen vierteljährlichen Raten von 6,25% mit einem endgültigen Vesting-Datum am 14. Februar 2026, abhängig von fortgesetzter Dienstzeit. Das Formular 4 wurde am 18. August 2025 von einem Bevollmächtigten im Namen von Frau Soares unterschrieben.

Positive
  • Substantial retained ownership: Reporting Person retains 1,469,487 Class A shares after the withholding, indicating continued insider alignment.
  • Clear vesting schedule disclosed: Remaining RSUs vest quarterly with a final vesting date of February 14, 2026, providing transparency on future potential insider holdings.
Negative
  • Reduction in beneficial ownership: 7,459 Class A shares were disposed via withholding to cover taxes upon RSU vesting.

Insights

TL;DR: Routine tax‑withholding sale on RSU vesting; substantial retained stake remains, so minimal market impact.

The reported disposal of 7,459 shares at $2.57 per share reflects automatic withholding to satisfy tax obligations upon vesting of a scheduled tranche of time‑based RSUs. This transaction is administrative, not an opportunistic open‑market sale, and the Reporting Person continues to hold 1,469,487 Class A shares, which is materially larger than the withheld amount. For investors, this indicates continued insider alignment with the company through ongoing equity holdings while complying with tax mechanics tied to compensation.

TL;DR: Disclosure is standard and compliant; vesting schedule and withholding are clearly documented.

The Form 4 provides the required details: transaction date, amount withheld, withholding price, and an explicit explanation that the shares were withheld to cover taxes upon vesting of RSUs granted in February 2022. The filing also states the remaining vesting timeline through February 14, 2026. The presence of attorney‑in‑fact signature indicates proper execution. This is a routine insider compensation event with no indication of governance concern from the facts reported.

Karen M. Soares, General Counsel & Secretary di Clover Health Investments, Corp. (CLOV), ha comunicato una ritenuta ordinaria su unità azionarie vincolate (RSU) maturate in data 14 agosto 2025. Il Modulo 4 indica che 7.459 azioni di azioni ordinarie di Classe A sono state cedute a un prezzo implicito di ritenuta di $2,57 per azione per coprire le imposte legate alla maturazione del 6,25% delle RSU originariamente assegnate il 14 febbraio 2022. Dopo questa ritenuta, la persona che presenta la comunicazione detiene beneficiariamente 1.469.487 azioni ordinarie di Classe A.

La comunicazione descrive il calendario delle RSU: la quota del 6,25% è maturata il 14 agosto 2025, mentre le restanti RSU basate sul tempo matureranno in quote trimestrali uguali del 6,25% con data finale di maturazione il 14 febbraio 2026, subordinata alla continuazione del servizio. Il Modulo 4 è stato firmato da un procuratore il 18 agosto 2025 per conto della Sig.ra Soares.

Karen M. Soares, Consejera General y Secretaria de Clover Health Investments, Corp. (CLOV), reportó una retención rutinaria de unidades de acciones restringidas (RSU) adquiridas el 14 de agosto de 2025. El Formulario 4 muestra que se dispusieron 7.459 acciones ordinarias de Clase A a un precio implícito de retención de $2,57 por acción para cubrir obligaciones fiscales vinculadas al otorgamiento del 6,25% de las RSU originalmente concedidas el 14 de febrero de 2022. Tras esta retención, la persona informante posee beneficiariamente 1.469.487 acciones ordinarias de Clase A.

La presentación explica el calendario de las RSU: la porción del 6,25% venció el 14 de agosto de 2025, y las RSU restantes basadas en el tiempo vencerán en cuotas trimestrales iguales del 6,25% con una fecha final de vencimiento el 14 de febrero de 2026, condicionada a la continuidad del servicio. El Formulario 4 fue firmado por un apoderado en nombre de la Sra. Soares el 18 de agosto de 2025.

클로버 헬스 인베스트먼트 코퍼레이션(CLOV)의 법률 고문 겸 서기인 카렌 M. 소아레스(Karen M. Soares)는 2025년 8월 14일에 취득한 제한부주식단위(RSU)에 대해 통상적인 원천징수를 보고했습니다. Form 4에 따르면 7,459주 클래스 A 보통주가 주당 $2.57의 암묵적 원천징수 가격으로 처분되어 2022년 2월 14일에 원래 부여된 RSU의 6.25%의 취득과 관련된 세금 의무를 충당했습니다. 이 원천징수 후 보고인은 클래스 A 보통주 1,469,487주를 실질적으로 보유하게 되었습니다.

보고서에는 RSU 일정이 설명되어 있습니다: 6.25% 분량은 2025년 8월 14일에 취득되었고, 나머지 기간기반 RSU는 동일한 분기별 6.25%씩 분할 취득되며 최종 취득일은 2026년 2월 14일로서 계속 근무가 조건입니다. Form 4는 2025년 8월 18일 소아레스 씨를 대신하여 법정대리인(변호사)이 서명했습니다.

Karen M. Soares, conseillère juridique générale et secrétaire de Clover Health Investments, Corp. (CLOV), a signalé une retenue courante sur des unités d'actions restreintes (RSU) acquises le 14 août 2025. Le formulaire 4 indique que 7 459 actions ordinaires de classe A ont été cédées à un prix implicite de retenue de 2,57 $ par action pour couvrir des obligations fiscales liées à la vesting de 6,25 % des RSU initialement attribuées le 14 février 2022. Après cette retenue, la personne déclarante détient bénéficiairement 1 469 487 actions ordinaires de classe A.

Le dépôt explique le calendrier des RSU : la tranche de 6,25 % a vesté le 14 août 2025, les RSU restantes liées au temps vestant par tranches trimestrielles égales de 6,25 % avec une date finale de vesting le 14 février 2026, sous réserve de la poursuite du service. Le formulaire 4 a été signé le 18 août 2025 par un mandataire au nom de Mme Soares.

Karen M. Soares, General Counsel & Secretary von Clover Health Investments, Corp. (CLOV), meldete eine routinemäßige Einbehaltung von ausgeübten Restricted Stock Units (RSUs) am 14. August 2025. Das Formular 4 zeigt, dass 7.459 Aktien der Klasse A zum impliziten Einbehaltungspreis von $2,57 je Aktie veräußert wurden, um steuerliche Verpflichtungen im Zusammenhang mit der Vesting von 6,25% der ursprünglich am 14. Februar 2022 gewährten RSUs zu decken. Nach dieser Einbehaltung besitzt die meldepflichtige Person wirtschaftlich 1.469.487 Aktien der Klasse A.

Die Einreichung erläutert den RSU-Zeitplan: Der 6,25%-Anteil ist am 14. August 2025 vested, die verbleibenden zeitabhängigen RSUs vesten in gleichen vierteljährlichen Raten von 6,25% mit einem endgültigen Vesting-Datum am 14. Februar 2026, abhängig von fortgesetzter Dienstzeit. Das Formular 4 wurde am 18. August 2025 von einem Bevollmächtigten im Namen von Frau Soares unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Soares Karen

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 08/14/2025 F 7,459(1) D $2.57 1,469,487 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on August 14, 2025, of 6.25% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on February 14, 2022. The remaining RSUs vest quarterly in equal installments of 6.25%, with a final vesting date occurring on February 14, 2026, subject to the continued service of the Reporting Person on each such vesting date.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Karen M. Soares 08/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Karen M. Soares report on Form 4 for CLOV?

The Form 4 reports that 7,459 Class A shares were disposed of on 08/14/2025 via automatic withholding to cover taxes upon RSU vesting.

How many CLOV shares does the Reporting Person beneficially own after the transaction?

After the reported withholding, the Reporting Person beneficially owns 1,469,487 Class A common shares.

Why were the 7,459 CLOV shares disposed of?

The shares were automatically withheld to satisfy tax obligations when 6.25% of the original time‑based RSUs granted on 02/14/2022 vested on 08/14/2025.

What is the remaining RSU vesting schedule disclosed in the filing?

The filing states remaining RSUs vest in equal quarterly installments of 6.25% each, with a final vesting date of 02/14/2026, subject to continued service.

Who signed the Form 4 on behalf of the Reporting Person?

The Form 4 was signed by Peter J. Rivas as attorney‑in‑fact for Karen M. Soares on 08/18/2025.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.36B
403.52M
3.77%
27.27%
7.11%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
JERSEY CITY